Mr. Eric So reports

HELUS PHARMA ANNOUNCES CHIEF EXECUTIVE OFFICER TRANSITION; ERIC SO TO RESUME ROLE AS INTERIM CHIEF EXECUTIVE OFFICER

Cybin Inc.'s (Helus Pharma) Michael Cola is stepping down as chief executive officer, effective immediately, at the request of the board of directors.

The board has appointed co-founder and executive chairman Eric So to resume his role as interim chief executive officer, effective immediately, while a search for a successor is conducted. Mr. So previously served as interim chief executive officer and brings continuity of leadership during this transition.

"Helus Pharma was founded with a clear mission: to advance innovative therapies that address serious unmet needs in mental health," said Eric So, interim chief executive officer. "With a strong foundation of clinical progress, regulatory recognition and dedicated teams, we remain well positioned to continue advancing our programs. I am committed to ensuring continuity during this transition and maintaining our focus on creating long-term value for both patients and shareholders."

Mr. So continued: "Our priorities remain clear as we execute on our strategy, advance our clinical pipeline and work closely with our partners to deliver meaningful therapeutic options for patients. In particular, our focus remains on the upcoming top-line data readout from the ApproacH trial of HLP003 expected in the fourth quarter, and we remain committed to disciplined execution and supporting our teams as we move forward."

Mr. So is a co-founder and executive chairman of Helus Pharma. He is a veteran owner and operator over the last 20 years, and has led corporate strategy, development and finance at all stages of the business life cycle from start-up to growth stage and multinational.

The board of directors has initiated a search process to identify a permanent chief executive officer.

About Helus Pharma

Helus Pharma, the commercial operating name of Cybin Inc., is a clini/cal stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs -- novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety and other mental health conditions.

With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received breakthrough therapy designation from the United States Food and Drug Administration and HLP004, also a proprietary NSA in phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The company operates in Canada, the United States, the United Kingdom and Ireland.

We seek Safe Harbor.